Replacing renal function using bioengineered tissues
Source abstract
Abstract
Kidney transplantation is at present the only definitive treatment for patients with end-stage kidney disease that can improve the quality of life compared with dialysis. However, donor organs are of limited availability. The question is whether kidney tissues can be engineered to provide renal replacement therapy. In this Review, we outline key challenges in renal replacement and examine the clinical potential, current limitations and ethical considerations of bioengineering approaches aimed at replacing renal function, including kidney decellularization and recellularization, ex vivo kidney engineering, xenotransplantation, blastocyst complementation and kidneys derived from pluripotent stem cells. Finally, we highlight key hurdles that remain to be addressed to translate bioengineered kidney approaches to the clinic, including product scalability, ex vivo tissue preservation and good manufacturing practice.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Renal and related cancers · Organ Donation and Transplantation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. 12, 7–11 (2022).10.1016/j.kisu.2021.11.003 ↗
2. Humes, H. D. et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int. 66, 1578–1588 (2004).10.1111/j.1523-1755.2004.00923.x ↗
3. Westover, A. J. et al. A bio-artificial renal epithelial cell system conveys survival advantage in a porcine model of septic shock. J. Tissue Eng. Regen. Med. 11, 649–657 (2017).10.1002/term.1961 ↗
4. Fissell, W. H. & Roy, S. The implantable artificial kidney. Semin. Dial. 22, 665–670 (2009).10.1111/j.1525-139X.2009.00662.x ↗
5. Brunswig-Spickenheier, B. et al. Limited immune-modulating activity of porcine mesenchymal stromal cells abolishes their protective efficacy in acute kidney injury. Stem Cell Dev. 19, 719–729 (2010).10.1089/scd.2009.0494 ↗
6. Tögel, F. et al. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cell Dev. 18, 475–485 (2009).10.1089/scd.2008.0092 ↗
7. Westenfelder, C. & Togel, F. E. Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials. Kidney Int. Suppl. 1, 103–106 (2011).10.1038/kisup.2011.24 ↗
8. Dreyer, G. J. et al. Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: the Neptune study, a phase I single-center study. Am. J. Transpl. 20, 2905–2915 (2020).10.1111/ajt.15910 ↗
9. Reinders, M. E., Rabelink, T. J. & de Fijter, J. W. The role of mesenchymal stromal cells in chronic transplant rejection after solid organ transplantation. Curr. Opin. Organ. Transpl. 18, 44–50 (2013).10.1097/MOT.0b013e32835c2939 ↗
10. Reinders, M. E. J. et al. Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: the randomized prospective, single-center, open-label TRITON study. Am. J. Transpl. 21, 3055–3065 (2021).10.1111/ajt.16528 ↗
11. Bellini, M. I. & D’Andrea, V. Organ preservation: which temperature for which organ? J. Int. Med. Res. 47, 2323–2325 (2019).10.1177/0300060519833889 ↗
12. Osband, A. J., James, N. T. & Segev, D. L. Extraction time of kidneys from deceased donors and impact on outcomes. Am. J. Transpl. 16, 700–703 (2016).10.1111/ajt.13457 ↗
13. Cooper, D. K. C. et al. Clinical pig kidney xenotransplantation: how close are we? J. Am. Soc. Nephrol. 31, 12–21 (2020).10.1681/ASN.2019070651 ↗
14. Naik, R. H. & Shawar, S. H. Renal Transplantation Rejection. In: StatPearls. StatPearls Publishing (2023).
15. Cheung, C. Y. & Tang, S. C. W. An update on cancer after kidney transplantation. Nephrol. Dial. Transpl. 34, 914–920 (2019).10.1093/ndt/gfy262 ↗
16. Balzer, M. S., Rohacs, T. & Susztak, K. How many cell types are in the kidney and what do they do?Annu. Rev. Physiol. 84, 507–531 (2022).10.1146/annurev-physiol-052521-121841 ↗
17. Hansen, J. et al. A reference tissue atlas for the human kidney. Sci. Adv. 8, eabn4965 (2022).10.1126/sciadv.abn4965 ↗
18. Steffes, M. W., Schmidt, D., McCrery, R. & Basgen, J. M. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 59, 2104–2113 (2001).10.1046/j.1523-1755.2001.00725.x ↗
19. Destefani, A. C., Sirtoli, G. M. & Nogueira, B. V. Advances in the knowledge about kidney decellularization and repopulation. Front. Bioeng. Biotechnol. 5, 34 (2017).10.3389/fbioe.2017.00034 ↗
20. Crapo, P. M., Gilbert, T. W. & Badylak, S. F. An overview of tissue and whole organ decellularization processes. Biomaterials 32, 3233–3243 (2011).10.1016/j.biomaterials.2011.01.057 ↗
21. Paulo Zambon, J., Atala, A. & Yoo, J. J. Methods to generate tissue-derived constructs for regenerative medicine applications. Methods 171, 3–10 (2020).10.1016/j.ymeth.2019.09.016 ↗
22. Taylor, D. A. et al. Characterization of perfusion decellularized whole animal body, isolated organs, and multi-organ systems for tissue engineering applications. Physiol. Rep. 9, e14817 (2021).10.14814/phy2.14817 ↗
23. de Haan, M. J. A., Witjas, F. M. R., Engelse, M. A. & Rabelink, T. J. Have we hit a wall with whole kidney decellularization and recellularization: a review. Curr. Opin. Biomed. Eng. 20, 100335 (2021).10.1016/j.cobme.2021.100335 ↗
24. Caralt, M. et al. Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am. J. Transpl. 15, 64–75 (2015).10.1111/ajt.12999 ↗
25. Aamodt, J. M. & Grainger, D. W. Extracellular matrix-based biomaterial scaffolds and the host response. Biomaterials 86, 68–82 (2016).10.1016/j.biomaterials.2016.02.003 ↗
26. Sambi, M. et al. Acellular mouse kidney ECM can be used as a three-dimensional substrate to test the differentiation potential of embryonic stem cell derived renal progenitors. Stem Cell Rev. Rep. 13, 513–531 (2017).10.1007/s12015-016-9712-2 ↗
27. He, M., Callanan, A., Lagaras, K., Steele, J. A. M. & Stevens, M. M. Optimization of SDS exposure on preservation of ECM characteristics in whole organ decellularization of rat kidneys. J. Biomed. Mater. Res. B 105, 1352–1360 (2017).10.1002/jbm.b.33668 ↗
28. Peloso, A. et al. Renal extracellular matrix scaffolds from discarded kidneys maintain glomerular morphometry and vascular resilience and retains critical growth factors. Transplantation 99, 1807–1816 (2015).10.1097/TP.0000000000000811 ↗
29. Ullah, I. et al. VEGF — supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC. Biomaterials 216, 119283 (2019).10.1016/j.biomaterials.2019.119283 ↗
30. Ullah, I. et al. Adult tissue extracellular matrix determines tissue specification of human iPSC-derived embryonic stage mesodermal precursor cells. Adv. Sci. 7, 1901198 (2020).10.1002/advs.201901198 ↗
31. Zambon, J. P. et al. Comparative analysis of two porcine kidney decellularization methods for maintenance of functional vascular architectures. Acta Biomater. 75, 226–234 (2018).10.1016/j.actbio.2018.06.004 ↗
32. Song, J. J. et al. Regeneration and experimental orthotopic transplantation of a bioengineered kidney. Nat. Med. 19, 646–651 (2013).10.1038/nm.3154 ↗
33. Ciampi, O. et al. Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells. Sci. Rep. 9, 8001 (2019).10.1038/s41598-019-44393-y ↗
34. Leuning, D. G. et al. Vascular bioengineering of scaffolds derived from human discarded transplant kidneys using human pluripotent stem cell-derived endothelium. Am. J. Transpl. 19, 1328–1343 (2019).10.1111/ajt.15200 ↗
35. Remuzzi, A. et al. Experimental evaluation of kidney regeneration by organ scaffold recellularization. Sci. Rep. 7, 43502 (2017).10.1038/srep43502 ↗
36. Bonandrini, B. et al. Recellularization of well-preserved acellular kidney scaffold using embryonic stem cells. Tissue Eng. Part. A 20, 1486–1498 (2014).10.1089/ten.tea.2013.0269 ↗
37. Ross, E. A. et al. Embryonic stem cells proliferate and differentiate when seeded into kidney scaffolds. J. Am. Soc. Nephrol. 20, 2338–2347 (2009).10.1681/ASN.2008111196 ↗
38. Bombelli, S. et al. Nephrosphere-derived cells are induced to multilineage differentiation when cultured on human decellularized kidney scaffolds. Am. J. Pathol. 188, 184–195 (2018).10.1016/j.ajpath.2017.09.012 ↗
39. Ko, I. K. et al. Enhanced re-endothelialization of acellular kidney scaffolds for whole organ engineering via antibody conjugation of vasculatures. Technology 2, 243–253 (2014).10.1142/S2339547814500228 ↗
40. Kim, I. H., Ko, I. K., Atala, A. & Yoo, J. J. Whole kidney engineering for clinical translation. Curr. Opin. Organ. Transpl. 20, 165–170 (2015).10.1097/MOT.0000000000000173 ↗
41. Ross, E. A. et al. Mouse stem cells seeded into decellularized rat kidney scaffolds endothelialize and remodel basement membranes. Organogenesis 8, 49–55 (2012).10.4161/org.20209 ↗
42. Xue, A. et al. Recellularization of well-preserved decellularized kidney scaffold using adipose tissue-derived stem cells. J. Biomed. Mater. Res. A 106, 805–814 (2018).10.1002/jbm.a.36279 ↗
43. Padalhin, A. R., Park, C. M. & Lee, B. T. Streamlined system for conducting in vitro studies using decellularized kidney scaffolds. Tissue Eng. Part C Methods 24, 42–55 (2018).10.1089/ten.tec.2017.0252 ↗
44. Uzarski, J. S. et al. Dual-purpose bioreactors to monitor noninvasive physical and biochemical markers of kidney and liver scaffold recellularization. Tissue Eng. Part C Methods 21, 1032–1043 (2015).10.1089/ten.tec.2014.0665 ↗
45. Uzarski, J. S. et al. Epithelial cell repopulation and preparation of rodent extracellular matrix scaffolds for renal tissue development. J. Vis. Exp. https://doi.org/10.3791/53271 (2015).10.3791/53271 ↗
46. Batchelder, C. A., Martinez, M. L. & Tarantal, A. F. Natural scaffolds for renal differentiation of human embryonic stem cells for kidney tissue engineering. PLoS ONE 10, e0143849 (2015).10.1371/journal.pone.0143849 ↗
47. Poornejad, N. et al. Re-epithelialization of whole porcine kidneys with renal epithelial cells. J. Tissue Eng. 8, 2041731417718809 (2017).10.1177/2041731417718809 ↗
48. Abolbashari, M. et al. Repopulation of porcine kidney scaffold using porcine primary renal cells. Acta Biomater. 29, 52–61 (2016).10.1016/j.actbio.2015.11.026 ↗
49. Abrahimi, P., Liu, R. & Pober, J. S. Blood vessels in allotransplantation. Am. J. Transpl. 15, 1748–1754 (2015).10.1111/ajt.13242 ↗
50. Kummer, L. et al. Vascular signaling in allogenic solid organ transplantation — the role of endothelial cells. Front. Physiol. 11, 443 (2020).10.3389/fphys.2020.00443 ↗
51. Elliott, T. R., Nicholson, M. L. & Hosgood, S. A. Normothermic kidney perfusion: an overview of protocols and strategies. Am. J. Transpl. 21, 1382–1390 (2021).10.1111/ajt.16307 ↗
52. Weissenbacher, A., Vrakas, G., Nasralla, D. & Ceresa, C. D. L. The future of organ perfusion and re-conditioning. Transpl. Int. 32, 586–597 (2019).10.1111/tri.13441 ↗
53. Cohen, S. et al. Generation of vascular chimerism within donor organs. Sci. Rep. 11, 13437 (2021).10.1038/s41598-021-92823-7 ↗
54. Kataria, A., Magoon, S., Makkar, B. & Gundroo, A. Machine perfusion in kidney transplantation. Curr. Opin. Organ. Transpl. 24, 378–384 (2019).10.1097/MOT.0000000000000675 ↗
55. Weissenbacher, A. et al. Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. Am. J. Transpl. 19, 178–192 (2019).10.1111/ajt.14932 ↗
56. Feng, B. et al. Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation 87, 1283–1289 (2009).10.1097/TP.0b013e3181a1905e ↗
57. Vos, I. H. et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J. 14, 815–822 (2000).10.1096/fasebj.14.5.815 ↗
58. Yang, C. et al. Serum-stabilized naked caspase-3 siRNA protects autotransplant kidneys in a porcine model. Mol. Ther. 22, 1817–1828 (2014).10.1038/mt.2014.111 ↗
59. Yuzefovych, Y. et al. Genetic engineering of the kidney to permanently silence MHC transcripts during ex vivo organ perfusion. Front. Immunol. 11, 265 (2020).10.3389/fimmu.2020.00265 ↗
60. Figueiredo, C. et al. Immunoengineering of the vascular endothelium to silence MHC expression during normothermic ex vivo lung perfusion. Hum. Gene Ther. 30, 485–496 (2019).10.1089/hum.2018.117 ↗
61. Rahfeld, P. et al. An enzymatic pathway in the human gut microbiome that converts A to universal O type blood. Nat. Microbiol. 4, 1475–1485 (2019).10.1038/s41564-019-0469-7 ↗
62. Wang, A. et al. Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs. Sci. Transl. Med. 14, eabm7190 (2022).10.1126/scitranslmed.abm7190 ↗
63. Sykes, M. & Sachs, D. H. Progress in xenotransplantation: overcoming immune barriers. Nat. Rev. Nephrol. https://doi.org/10.1038/s41581-022-00624-6 (2022).10.1038/s41581-022-00624-6 ↗
64. Cooper, D. K. et al. The pathobiology of pig-to-primate xenotransplantation: a historical review. Xenotransplantation 23, 83–105 (2016).10.1111/xen.12219 ↗
65. Cowan, P. J., Cooper, D. K. & d’Apice, A. J. Kidney xenotransplantation. Kidney Int. 85, 265–275 (2014).10.1038/ki.2013.381 ↗
66. Fischer, K. et al. Viable pigs after simultaneous inactivation of porcine MHC class I and three xenoreactive antigen genes GGTA1, CMAH and B4GALNT2. Xenotransplantation 27, e12560 (2020).10.1111/xen.12560 ↗
67. Lai, L. et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295, 1089–1092 (2002).10.1126/science.1068228 ↗
68. Längin, M. et al. Cold non-ischemic heart preservation with continuous perfusion prevents early graft failure in orthotopic pig-to-baboon xenotransplantation. Xenotransplantation 28, e12636 (2021).10.1111/xen.12636 ↗
69. Ma, D. et al. Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques. Am. J. Transpl. 22, 46–57 (2022).10.1111/ajt.16780 ↗
70. Niu, D. et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science 357, 1303–1307 (2017).10.1126/science.aan4187 ↗
71. Yang, L. et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs).Science 350, 1101–1104 (2015).10.1126/science.aad1191 ↗
72. Zhu, A. & Hurst, R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9, 376–381 (2002).10.1034/j.1399-3089.2002.02138.x ↗
73. Yue, Y. et al. Extensive germline genome engineering in pigs. Nat. Biomed. Eng. 5, 134–143 (2021).10.1038/s41551-020-00613-9 ↗
74. Adams, A. B. et al. Xenoantigen deletion and chemical immunosuppression can prolong renal xenograft survival. Ann. Surg. 268, 564–573 (2018).10.1097/SLA.0000000000002977 ↗
75. Porrett, P. M. et al. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am. J. Transpl. 22, 1037–1053 (2022).10.1111/ajt.16930 ↗
76. Montgomery, R. A. et al. Results of two cases of pig-to-human kidney xenotransplantation. N. Engl. J. Med. 386, 1889–1898 (2022).10.1056/NEJMoa2120238 ↗
77. Barth, R. N. et al. Xenogeneic thymokidney and thymic tissue transplantation in a pig-to-baboon model: I. Evidence for pig-specific T-cell unresponsiveness. Transplantation 75, 1615–1624 (2003).10.1097/01.TP.0000064335.50622.20 ↗
78. Griffith, B. P. et al. Genetically modified porcine-to-human cardiac xenotransplantation. N. Engl. J. Med. 387, 35–44 (2022).10.1056/NEJMoa2201422 ↗
79. Denner, J. et al. Impact of porcine cytomegalovirus on long-term orthotopic cardiac xenotransplant survival. Sci. Rep. 10, 17531 (2020).10.1038/s41598-020-73150-9 ↗
80. Gardner, R. L. & Johnson, M. H. Investigation of early mammalian development using interspecific chimaeras between rat and mouse. Nat. N. Biol. 246, 86–89 (1973).10.1038/newbio246086a0 ↗
81. Rossant, J. & Frels, W. I. Interspecific chimeras in mammals: successful production of live chimeras between Mus musculus and Mus caroli. Science 208, 419–421 (1980).10.1126/science.7367871 ↗
82. Kobayashi, T. et al. Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell 142, 787–799 (2010).10.1016/j.cell.2010.07.039 ↗
83. Goto, T. et al. Generation of pluripotent stem cell-derived mouse kidneys in Sall1-targeted anephric rats. Nat. Commun. 10, 451 (2019).10.1038/s41467-019-08394-9 ↗
84. Matsunari, H. et al. Compensation of disabled organogeneses in genetically modified pig fetuses by blastocyst complementation. Stem Cell Rep. 14, 21–33 (2020).10.1016/j.stemcr.2019.11.008 ↗
85. Yamaguchi, T. et al. Interspecies organogenesis generates autologous functional islets. Nature 542, 191–196 (2017).10.1038/nature21070 ↗
86. Kobayashi, T., Kato-Itoh, M. & Nakauchi, H. Targeted organ generation using Mixl1-inducible mouse pluripotent stem cells in blastocyst complementation. Stem Cell Dev. 24, 182–189 (2015).10.1089/scd.2014.0270 ↗
87. Wu, J. et al. Interspecies chimerism with mammalian pluripotent stem cells. Cell 168, 473–486.e415 (2017).10.1016/j.cell.2016.12.036 ↗
88. Tan, T. et al. Chimeric contribution of human extended pluripotent stem cells to monkey embryos ex vivo. Cell 184, 2020–2032.e2014 (2021).10.1016/j.cell.2021.03.020 ↗
89. Nishimura, T. et al. Generation of functional organs using a cell-competitive niche in intra- and inter-species rodent chimeras. Cell Stem Cell 28, 141–149.e143 (2021).10.1016/j.stem.2020.11.019 ↗
90. Roodgar, M. et al. Chimpanzee and pig-tailed macaque iPSCs: improved culture and generation of primate cross-species embryos. Cell Rep. 40, 111264 (2022).10.1016/j.celrep.2022.111264 ↗
91. Kobayashi, T. et al. Blastocyst complementation using Prdm14-deficient rats enables efficient germline transmission and generation of functional mouse spermatids in rats. Nat. Commun. 12, 1328 (2021).10.1038/s41467-021-21557-x ↗
92. Mori, M. et al. Generation of functional lungs via conditional blastocyst complementation using pluripotent stem cells. Nat. Med. 25, 1691–1698 (2019).10.1038/s41591-019-0635-8 ↗
93. Yamazaki, K. et al. In vitro and in vivo functions of T cells produced in complemented thymi of chimeric mice generated by blastocyst complementation. Sci. Rep. 12, 3242 (2022).10.1038/s41598-022-07159-7 ↗
94. Hyun, I. et al. ISSCR guidelines for the transfer of human pluripotent stem cells and their direct derivatives into animal hosts. Stem Cell Rep. 16, 1409–1415 (2021).10.1016/j.stemcr.2021.05.005 ↗
95. Yamanaka, S. et al. Generation of interspecies limited chimeric nephrons using a conditional nephron progenitor cell replacement system. Nat. Commun. 8, 1719 (2017).10.1038/s41467-017-01922-5 ↗
96. Fujimoto, T. et al. Generation of human renal vesicles in mouse organ niche using nephron progenitor cell replacement system. Cell Rep. 32, 108130 (2020).10.1016/j.celrep.2020.108130 ↗
97. Saito, Y. et al. Generation of functional chimeric kidney containing exogenous progenitor-derived stroma and nephron via a conditional empty niche. Cell Rep. 39, 110933 (2022).10.1016/j.celrep.2022.110933 ↗
98. Freedman, B. S. et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat. Commun. 6, 8715 (2015).10.1038/ncomms9715 ↗
99. Morizane, R. et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat. Biotechnol. 33, 1193–1200 (2015).10.1038/nbt.3392 ↗
100. Taguchi, A. et al. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell 14, 53–67 (2014).10.1016/j.stem.2013.11.010 ↗